Citations

Clear

82 citation(s) found for "Halle, Martin".

Serglycin as a Preliminary Candidate Biomarker in GNE Myopathy Associated with Impaired Secretion and Autophagy Dysregulation
Derksen, Alexa , Dobelmann, Vera , Hentschel, Andreas, Baird, Stephen, Holland, Stephen Henry , Chen, Lei, Ruck, Tobias, Horstkorte, Rüdiger, Milone, Margherita , Roos, Andreas, Hentschel, Andreas , Baird, Stephen D. , Ruck, Tobias , Doles, Jason D. , Evangelista, Teresinha , Spendiff, Sally , Roos, Andreas , Lochmüller, Hanns

Mayo Clinic

No container title available | June 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9791335/v1 Get It

Abstract GNE myopathy (GNEM) is a neuromuscular disorder caused by biallelic mutations in the gene GNE , which encodes a bifunctional enzyme essential for the biosynthesis of sialic acid. Despite extensive characterization, no effective therapies or validated biomarkers exist, and the molecular mechanisms driving disease pathology remain poorly understood. This study identifies the proteoglycan serglycin as a preliminary candidate biomarker in GNEM and investigates the mechanisms underlying its dysregulation. Proteomic analysis of serum samples from GNEM patients revealed reduced circulating serglycin levels. In contrast, increased intracellular serglycin was observed in GNE knockout and GNEM patient iPSC-derived myoblasts, suggesting impaired secretion and/or degradation. To investigate the basis of this accumulation, intracellular trafficking and autophagic pathways were examined. Proteomic profiling from HEK GNE knockout cells revealed alterations in pathways involved in membrane trafficking, Golgi function, and glycoprotein processing, consistent with broader disruptions in the secretory system that may impair serglycin export and contribute to its intracellular retention. In GNEM iPSC-derived myoblasts, serglycin overlapped with LAMP1-positive lysosomal compartments and the ER-phagy receptor FAM134B, suggesting association with lysosomal and ER-phagy related pathways. Functional assays further indicated impaired autophagic flux in mutant cells. Together, these findings support a model in which combined defects in secretion and autophagic clearance contribute to intracellular serglycin accumulation and reduced circulating levels. This study identifies serglycin as a potential circulating biomarker for GNEM and highlights dysregulation of secretory and degradative pathways as converging features of disease pathology.
Functional Outcomes in Bipolar Disorder: Cross-Cohort Analyses from the Global Bipolar Cohort
Yocum, *Anastasia K., Fullerton, *Janice M., Ashton, Melanie M., Overs, Browyn J., Diaz‐Byrd, Claudia , Albarracín-García, Lucía , Alda, Martin, Alexander, Nina , Altimus, Cara M. , Altınbaş, Kürşat, Andreassen, Ole A., Aubin, V. , Baca-García, Enrique, Baune, Bernhard T., Belzeaux, Raoul , Benavente-López, Sergio, Bengesser, Susanne A., Berk, Michael, Biernacka, Joanna, Blumberg, Hilary P., Burdick, Katherine E., Carpiniello, Bernardo, Chang, Chiao-Erh , Chen, Wen Yin, Clark, Scott R., Cleare, Anthony J., Contu, Martina , Dafnas, Konstantinos , Dannlowski, Udo, Dikeos, Dimitris, Dodd, Seetal, Dols, Annemieke, Dubertret, C, Etain, Bruno, Eyler, Lisa T., Fatjó‐Vilas, Mar , Ferentinos, Panagiotis, Ferguson, B. , Fernández, Ana L., Flinkenflügel, Kira, Forester, Brent P. , Fries, Gabriel R., Frye, Mark A., Fuentes-Claramonte, Paola, Gard, Sébastien, Gergel, Tania, Godin, O, Green, MJ, Haffen, E, Hahn, Tim, Havard, Alys, Jamalabadi, Hamidreza, Jansen, Andreas, Jones, I, Jones, Lisa A., Kelsoe, John R., Kircher, Tilo, Klaus, Federica, Kulkarni, Jayashri , Kupka, Ralph W., Leboyer, M, Lenger, Melanie , McElroy, Susan L., Machado-Vieira, Rodrigo, Manchia, Mirko, Martin, Nicolas G., Mata-Iturralde, Laura, Meinert, Susanne, Mitchell, Philip B., Mitra, Romita, Mohebbi, Mohammadreza , Mwangi, Benson, Nenadić, Igor, Nierenberg, Andrew A., Nunes, Abraham, Olié, E, O'Donovan, Clair, Orhan, Melis M., Passerieux, Christine, Perich, Tania, Peters, Amy T. , Petite, Joanne, Pham, Dániel , Pinna, M A, Platzer, Martina, Polosan, Mircea , Pomarol-Clotet, Edith, Porta-Casteràs, Daniel, Potter, Julia R., Quidé, Yann, Regeer, Eline J. , Rheenen, Tamsyn E. Van, Roberts, Gloria, Rodríguez-Cano, Elena, Rossell, Susan L., Sajatovic, Martha, Salvador, Raymond, Samalin, Ludovic, Sánchez-Alonso, Sergio, Sarró, Salvador , Schubert, Klaus O., Schwan, R, Scott, Katie , Shanahan, Megan, Soares, Jair C., Solé, Brisa, Stein, Dan J., Stein, Frederike, Strakowski, Stephen M., Straube, Benjamin, Strawbridge, Rebecca, Sullivan, Patrick F., Teutenberg, Lea, Thiel, Katharina , Thomas-Odenthal, Florian, Toma, Claudio, Usemann, Paula L., Vieta, Eduard, Vilella, Elisabet, Viswanath, Biju, Williams, Lana J., Wu, Mon-Ju, Yatham, Lakshmi N., Young, Allan H., McInnis, Melvin G., Almeida, Jorge, Bora, Emre, Cannon, Dara M., Chang, Yun-Hsuan, Chaumette, Boris, Chen, Jun, Ching, Christopher, Escamilla, Michael , Forstner, Andreas J., Goghari, Vina M. , He, Qin, Huang, Hailiang, Juruena, Mario F.; id_orcid 0000-0001-8558-3396, Kasyanov, Evgeny D., Koenig, B., Kovács, Zoltán , Kulkarni, Alok, Lee, Heon-Jeong, Lee, Jimmy, Liao, Duanping , LICHT, RASMUS W., Melle, Ingrid, Nicolini, Humberto, Okawa-Belizario, Gabriel, Prieto, Miguel L. , Raventós, Henriette , Ardestani, Seyed M. Samimi, Saunders, Erika F., Savitz, Jonathan, Schulze, Thomas G., Serretti, Alessandro, Simhandl, Christian , Straszek, Sune, SOUSA, RAFAEL TEIXEIRA DE , Thompson, Paul M., Tondo, Leonardo, Tourjman, S. Valérie, Zandi, Peter, Quidé, Yann , Overs, Bronwyn J. , Quidé, Yann , Sarró, Salvador , Yocum, Anastasia K. , Fullerton, Janice M. , Ashton, Melanie M. , Alda, Martin , Alonso-Lana, Sílvia , Altınbaş, Kürşat , Andreassen, Ole A , Antoniou, Anastasia , Baca‐García, Enrique , Baune, Bernhard T., López, Sergio Benavente , Berk, Michael , Beunders, Alexandra J.M. , Blumberg, Hilary P. , Brosch, Katharina , Burdick, Katherine E. , Callahan, Tiffany J , Cano, Marta , Cardoner, Narcı́s , Carpiniello, Bernardo , Chen, I‐Ming , Clark, Scott , Cleare, Anthony J. , Dalkner, Nina , Dannlowski, Udo , Dikeos, Dimitris, Dodd, Seetal , Dols, Annemiek , Dubertret, Caroline , Étain, Bruno , Eyler, Lisa T. , Fellendorf, Frederike T. , Flinkenflügel, Kira , Di Florio, Arianna , Fries, Gabriel R. , Frye, Mark A. , Fuentes‐Claramonte, Paola , Gergel, Tania , Godin, Ophélia , Gordon‐Smith, Katherine , Haffen, Emmanuel , Hahn, Tim , Hartmann, Simon , Havard, Alys , Hickie, Ian Bernard , Jamalabadi, Hamidreza , Jansen, Andreas , Kelsoe, John R , Kircher, Tilo , Klaus, Federica , Kuo, Po‐Hsiu , Kupka, Ralph , Lagerberg, Trine Vik , Leboyer, Marion , Lind, Penelope A. , McElroy, Susan L. , Machado‐Vieira, Rodrigo , Manchia, Mirko , Martínez‐Arán, Anabel , Medland, Sarah E. , Meinert, Susanne L. , Miklowitz, David J. , Millett, Caitlin E. , Mitchell, Philip B , Muntané, Gerard , Mwangi, Benson , Nenadić, Igor , Nierenberg, Andrew A. , Nurnberger, John I , Olié, Émilie , Orhan, Melis , Paribello, Pasquale , Passerieux, Christine , Perich, Tania , Pisanu, Claudia , Pomarol‐Clotet, Edith , Casteràs, Daniel Porta , Potter, Julia R, Reininghaus, Eva , Van Rheenen, Tamsyn , Ringin, Elysha , Ritter, Philipp , Roberts, Gloria, Rodríguez‐Cano, Elena , Rossell, Susan Lee , Sajatovic, Martha , Samalin, Ludovic , Scaini, Giselli , Schofield, Peter R. , Schouws, Sigfried N. T. M. , Schubert, Klaus Oliver , Schwan, Raymund , Shanahan, Megan, Siskind, Dan , Soares, Jair C. , Squassina, Alessio , Stein, Dan J. , Stein, Frederike , Strakowski, Stephen M. , Straube, Benjamin , Strawbridge, Rebecca , Stuart, Amanda L. , Teutenberg, Lea , Thomas‐Odenthal, Florian , Toma, Claudio , Torres, Ivan J. , Tsapekos, Dimosthenis , Ueland, Torill , Usemann, Paula L , Vieta, Eduard , Vilella, Elisabet , Viswanath, Biju , Winter, Alexandra , Wootton, Olivia , Wrobel, Anna L , Yatham, Lakshmi N. , Young, Allan H. , McInnis, Melvin G. , Bora, Emre , Cannon, Dara M. , Chaumette, Boris , Forstner, Andreas J. , Grigoroiu‐Serbânescu, Maria , He, Qin , Juruena, Mário F. , Kasyanov, Evgeny Dmitrievich , Koenig, Barbara, Lafer, Beny , Vernal, Ditte Lammers , Lee, Heon‐Jeong , McMahon, Francis J. , McQuillin, Andrew , Melle, Ingrid , Najand, Babak , Nicolini, Humberto , Belizário, Gabriel Okawa , Redlich, Ronny , Ardestani, Seyed Mehdi Samimi , Saunders, Erika F.H. , Savitz, Jonathan B. , Schulze, Thomas , Serretti, Alessandro , Σκώκου, Μαρία , Straszek, Sune Puggaard Vogt , Sousa, Rafael Teixeira de, Thompson, Paul M. , Tondo, Leonardo , Xiong, Ashley

Mayo Clinic

No container title available | May 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9390347/v1 Get It

Abstract Background The Global Bipolar Cohort (GBC) was established to identify existing bipolar disorder (BD) cohorts worldwide and foster collaborations focused on descriptive and analytic outcomes relevant to BD. A distributed analytic framework has been implemented to engage multiple sites without the need for central data pooling. This report describes the GBC endeavor and global functional impairment patterns. Cross-cohort comparisons of functional correlates are limited by heterogeneous measures and data-sharing constraints. Large, culturally diverse comparisons are needed to distinguish broadly reproducible correlates from cohort-specific effects. Participating sites completed a 28-item descriptive survey covering diagnostic methods, cognition, genetics, treatment, functioning, and follow-up strategies. We implemented a harmonized local logistic regression model of dichotomized functional outcome and shared summary statistics only. Results We identified 69 cohorts across five continents. Thirty-seven cohorts contributed functional outcome analyses from 17,130 participants. Outcome measures included clinician-rated disability scales and social indicators such as employment and marital status. The proportion classified with poor functioning ranged from 16% to 77% (mean 50%). In 32 of 37 cohorts, the overall regression model significantly explained variance in functioning. Current depressive symptoms were the most robust and reproducible correlate of poor functional outcome: they were assessed in 29 cohorts, significant in 22 (75.8%), ranked among the top three correlates in 22, and were the top-ranked correlates in 19. Associations between depressive burden and poor functioning were observed across clinician-rated disability scales and work or social indicators, and across geographically diverse cohorts. Comorbid substance use disorder and medication-related variables were associated with poorer functioning in subsets of cohorts, whereas sex, ancestry, bipolar subtype, psychosis history, and premorbid IQ showed weak or inconsistent associations. Cognitive measures, available in a minority of regression models, showed modest and non-uniform effects. Conclusions Across heterogeneous international cohorts, current depressive symptom burden emerged as the most consistent correlate of poor functioning in bipolar disorder. These findings replicate earlier multisite work at a larger scale, show that protocol-based distributed analyses can identify reproducible clinical signals without sharing individual-level data, and support prioritizing detection and treatment of depressive symptoms when aiming to improve real-world functioning. Future work should expand longitudinal harmonization and representation of under-studied populations.
Contemporary Adjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasms
Haugk, Beate , White, Steven, Marchegiani, Giovanni, Holmberg, Marcus, Zerbi, Alessandro, Lu, Zipeng , Inoue, Y., Choi, Munseok , Kang, Chang Moo, Visser, B., Corpelijn, Lieke, Andersson, Bodil, Bereza-Carlson, Paulina, Björnsson, Bergthor, Wennerblom, Johanna, Goh, Brian K. P., Hartman, V., Ahmad, Syed, Patel, Sameer, Berrevoet, Frederik, Mortensen, Kim Erlend, Roberts, K., Lynch, Calum, Gupta, Amit, Kleeff, Joerg, Addeo, Pietro, Friess, Helmut, Koea, Jonathan, Gomez, Dhanny , Gordon-Weeks, Alex, Doria, Cataldo, Tzimas, Georgios, Franklin, O., Månsson, C., Cabús, Santiago Sánchez, Bhogal, Ricky H. , Pathak, Samir, Honselmann, Kim Christin, Balakrishnan, Anita, Mann, Kulbir , Gill, Anthony J., Mittal, A, Samra, Jas, Athwal, Tejinderjit, Loveday, Benjamin, Bhardwaj, Neil, Menon, Krishna, Thapa, Prabin, Matsumoto, Ippei, Jamieson, Nigel, Rebours, Vinciane, Descourvières, Clémence, Davidson, BR, Soreide, Kjetil, Pandanaboyana, Sanjay, Collaborative, Adeno-IPMN2, Kumar, Ajit, González, Carol Natalia Clavijo, Lam, Shi, L’Official-German, Ivan, Bergner, Tina, Rosso, Edoardo , Giulianotti, Pier Cristoforo , Morreau, Mathew , Dili, Alexandra, Sotiropoulou, Maria , Kuzman, Matta , Büyükkasap, Ahmet Çağrı, Uludağ, Gökhan, McGuigan, Mari-Claire , Chouari, Tarak , Dogul, Ahmet, Doğu, Doğukan , Rebelo, Artur, Holewik, Franziska Bernadette, Plesa-Furda, Roxana, Revoredo, Fernando, Galanis, Ilias , Maharjan, Dhiresh, Ghorbani, Poya , Lind, Max, Ami, Katsuya , Vijayashanker, Aarathi , Alsaoudi, Tareq , Lundgren, Linda , Ellisa, Katrina, Hong, Paul , Gupta, Archit, MartinXu, Congde, Konstantoudakis, Georgios, Christophides, Thalis, Spurring, Eleanor Margaret, Iwao, Yasuhito, Pirklc, Martin, Vaitha, Ruhi , Tiwari, Navneet, Sheel, Andrea, Kotecha, Krishna , Stavrou, Gregor A., Patel, Rikhilroy, Misca, Mihaela , Hammond, John, Roalso, Marcus Thomas Thor, Soomro, Faiza H, Halimi, Asif , Kendall, Timothy, Patel, Visad, Stankic, Dunja, Dries, Pieter , Hein, Charlotte, Betram, Julia, Jacob, Rosetta, Wilson, Gregory, Redas, Souheil, Poškus, Augustas, Mosert, Paula Lucia, Šilinskaitė, Ugnė , Hirose, Yuki, Liu, Xue, Standaert, Lars, Kay, Tegan J, Nishida, Kenji, Peddakota, Vivek , Gupta, Amit , Kang, Chang Moo , Ven Fong, Zhi, Kang, Chang Moo , Lucocq, James E. , Marchegiani, Giovanni , Zerbi, Alessandro , Pagnanelli, Michele , Visser, B. , Andersson, Bodil , Bereza‐Carlson, Paulina , Björnsson, Bergþór , Wennerblom, Johanna Hansson , Labori, Knut Jørgen , Goh, Brian K P , Hartman, Vera , Berrevoet, Frederik Christiaan , Ausania, Fabio , Bertrand, Claude , Kleeff, Joerg, Addeo, Pietro , Bellotti, Ruben , Fong, Zhi Ven , Friess, Helmut , Koea, Jonathan , Gordon-Weeks, Alex Nicolas , Doria, Cataldo , Franklin, Oskar , Pathak, Samir , Honselmann, Kim C. , Balakrishnan, Anita , Harrison, Ewen M. , Gill, A J, Mittal, Anubhav, Samra, Jas , Athwal, Tejinderjit , Loveday, Benjamin P. T. , Teh, Catherine , Bhardwaj, Neil , Menon, Krishna, Matsumoto, Ippei , Jamieson, Nigel , Rebours, Vinciane , Søreide, Kjetil , Martlı, Hüseyin Fahri , Roeyen, Geert , Antonakis, Pantelis T. , Bramis, Konstantinos , Hall, Lewis A , Valle, Valentina , Connor, Saxon J. , Kapiris, Stylianos A. , Kerem, Mustafa , Rebelo, Artur , Plesa-Furda, R., Filho, Omero Pereira da Costa , Galanis, Ilias, Konstantoudakis, Georgios, Christophides, Thalis, McGuinness, Matthew James , Yaqub, Sheraz , Pellegrini, Riccardo , Perri, Giampaolo , Sheel, Andrea , Sheen, Amy , Evans, Daisy, Ghamarnejad, Omid , Karavias, Dimitrios D. , Roalsø, Marcus T. T. , Stankic, Dunja , Grubor, Nikica , Gulla, Aistė , Furukawa, Takaaki , Hirose, Yuki , Yin, Lingdi , Inoue, Yosuke

Mayo Clinic

JAMA Network Open | March 27, 2026 | Volume: 9 | Issue: 3 | Pages: e263688

10.1001/jamanetworkopen.2026.3688 | PMID 41893840 Get It

Importance Adjuvant chemotherapy regimens may be administered after pancreatic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMNs), although the evidence supporting their use is limited. Objective To evaluate the survival benefit associated with contemporary adjuvant chemotherapy regimens after resection in A-IPMNs between 2017 and 2023. Design, Setting, and Participants This retrospective cohort study was an international, multicenter study with 69 participating centers across Europe, North America, South America, and the Asia-Pacific region. Patients undergoing resection for A-IPMNs were included. Data were analyzed from May to August 2025. Intervention Contemporary adjuvant chemotherapy regimens, such as gemcitabine-capecitabine (GemCap); 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX), modified FOLFIRINOX (mFOLFIRINOX), and S-1. Main Outcome and Measure Overall survival (months). Results Among 1321 patients (median [IQR] age 70 [63 to 76] years; 713 males [54.0%] and 608 females [46.0%]), 781 patients (59.1%) received adjuvant chemotherapy, while in 181 patients (13.7%) it was omitted due to poor patient fitness. Of patients who received adjuvant chemotherapy, 568 patients (72.6%) received contemporary regimens, including GemCap (232 patients [29.7%]), FOLFIRINOX (176 patients [22.5%]), mFOLFIRINOX (71 patients [9.1%]), and S-1 (70 patients [9.0%]). The median (IQR) follow-up for the cohort was 64.2 (40.4 to 85.0) months, and the median overall survival was 73.8 months (95% CI, 66.4 to 81.9 months). After 90-day landmark analysis and exclusion of patients ineligible for chemotherapy, adjuvant chemotherapy vs no adjuvant chemotherapy (propensity score–matched populations, 243:243 patients) was not associated with improved overall survival (median, 82.3 months; 95% CI, 78.2 months to not applicable [NA] vs not reached; 95% CI, 75.3 months to NA; P = .58). Contemporary regimens vs no adjuvant chemotherapy (propensity score–matched populations, 309:309 patients) was not associated with longer survival, and a mean survival benefit greater than 4.2 months over 5 years was excluded (difference in restricted mean survival, 1.26 months; 95%, −1.72 to 4.24 months). Treatment outcomes did not vary by chemotherapy regimen or disease characteristic (eg, N stage or carbohydrate antigen 19-9 level). Conclusions and Relevance In this study, contemporary adjuvant chemotherapy was not associated with improved overall survival in A-IPMNs, and a randomized clinical trial is indicated.
Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes
Garcia‐Manero, Guillermo , Saini, Lalit , Yacoub, Abdulraheem , Maness, Lori J., Foran, James M. , Lübbert, Michael , Lodewyck, Tom , Amin, Harshad, Bachiashvili, Kimo, Yimer, Habte, Zhu, Nancy , Lopez, Patricia Font, Priego, Victor, Odenike, Olatoyosi , Heyrman, Bert , Wan, Yubing, Chan, Winny, Oganesian, Aram , Sano, Yuri, Zeidan, Amer M. , Traer, Elie , Mohan, Sanjay , Xicoy, Blanca , Al‐Ali, Haifa Kathrin , Lopez, Patricia Font, Sanz, Guillermo , Santini, Valeria , Berdeja, Jesús G. , Valcárcel, David , Wan, Yubing, Keer, Harold N , Griffiths, Elizabeth A.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 790-790

10.1182/blood-2025-790 Get It

Abstract Background: Parenteral DNA methyltransferase inhibitors (DNMTi) such as azacitidine and decitabine (DEC), including an attenuated 3-day regimen, are recommended in the NCCN Guidelines for patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) with clinically significant cytopenias. However, parenteral administration requires frequent clinic visits, which imposes a substantial burden on pts, particularly those requiring long-term therapy. Oral DMTIs offer more flexible dosing and maintenance of pts' autonomy. Oral DEC-cedazuridine (DEC-C) is a fixed-dose combination tablet containing DEC (35 mg) and cedazuridine (100 mg). ASTX727-03 (NCT03502668) is a randomized, open-label, multicenter, phase 1/2 clinical trial evaluating safety, efficacy, and pharmacokinetics (PK) of various DEC-C doses and regimens in pts with LR-MDS. Phase 1 identified a 5-day regimen of DEC 10 mg/cedazuridine 100 mg as the optimized low-dose (LD) regimen. Phase 2 compares this LD regimen with the attenuated standard-dose (SD) regimen. Here, we report phase 2 results on efficacy, safety, PK, and pharmacodynamic (PD) data. Methods: Adults (aged ≥18 years) with International Prognostic Scoring System (IPSS) low-risk or Intermediate-1 MDS, ECOG PS 0−2, and ≥1 cytopenia or red blood cell (RBC) transfusion dependence were randomized 1:1 to receive oral DEC-C LD (10 mg x 5 days) or SD (35 mg x 3 days). The primary endpoint was hematologic response. Secondary endpoints included PK, PD (by LINE-1 demethylation), time to bone marrow blasts >5%, leukemia-free survival (LFS), overall survival (OS), and safety. Results: As of October 31, 2024, 81 pts were treated (LD arm: n=40; SD arm: n=41) and completed a median of 8.8 months on treatment. At cutoff, 17 (42.5%) and 12 (28.6%) LD and SD pts, respectively, were still continuing the study; 9 (22.5%) and 6 (14.6%) pts respectively, had discontinued treatment due to hematopoietic stem cell transplant. Median age was 70 (LD) and 75 (SD) years; 75.0% (LD) and 68.3% (SD) had IPSS Int-1 risk MDS and 60.0% vs 41.5% had IPSS-Molecular Lower-Risk MDS (very low, low, or moderate-low). Low-risk prognostic scoring system risk distribution was similar: Category 1 (2.5% vs 4.9%), Category 2 (47.5% vs 46.3%), and Category 3 (50.0% vs 48.8%). After a median follow-up of 29.3 months, median OS was 23.9 months (95% confidence interval [CI]: 13.0, not estimable [NE]) in the LD arm vs 26.0 months (95% CI: 19.4, 28.5) in the SD arm. Median LFS was 23.8 months (95% CI: 13.0, NE) and 25.7 months (95% CI: 17.8, 26.5), respectively. Hematologic improvement per International Working Group 2006 criteria was achieved in 27.5% (LD) and 26.8% (SD) of pts. Among RBC transfusion–dependent pts, 52.4% (LD) and 37.5% (SD) achieved ≥56-day independence and 47.6% (LD) and 20.8% (SD) achieved ≥112-day independence. Pts received a median of 10 (LD) and 9 (SD) cycles. Delayed cycles occurred in 72.5% (LD) vs 82.9% (SD) of pts; dose reductions occurred in 40.0% (LD) and 46.3% (SD) of pts. Both treatment regimens caused a decrease in blood counts, reaching a nadir before recovering in each cycle. Neutropenia was more pronounced during early cycles and was more severe in the SD arm. Blood counts across all lineages remained stable or improved through ≥12 cycles with the LD arm, suggesting a more favorable safety and tolerability profile. Grade ≥3 adverse events (AEs) occurred in 85.0% and 90.2% of pts in the LD and SD arms, respectively; treatment discontinuation due to AEs occurred in 2.5% and 17.1% of pts, respectively. Most commonly reported treatment-emergent AEs were anemia (42.5% LD, 39.0% SD), fatigue (32.5% LD, 43.9% SD), and thrombocytopenia (37.5% LD, 39.0% SD). Three deaths occurred in the trial: 2 in the LD arm, which were both unrelated to study treatment, and 1 in the SD arm (Pseudomonal bacteremia in Cycle 1), which was treatment related. Total AUC0–24 was 199 ng*h/mL in the LD arm and 465 ng*h/mL in the SD arm; AUC for all cycles of the LD arm was approximately half of the SD arm. Maximal % LINE-1 demethylation rate was lower with LD than SD, but narrowed by Cycle 3. Conclusion: LD oral DEC-C demonstrated comparable clinical benefit to SD oral DEC-C, with improved safety and tolerability, including fewer dose modifications and less severe myelosuppression. These findings support LD DEC-C as a potential optimal regimen for pts with LR-MDS. Clinical trial registration: NCT03502668
International Reference Values for Surgical Outcomes of Total Pancreatectomy
Berchtold, Caroline , Kuemmerli, Christoph, Li, Zhihao , Eden, Janina , Wu, Pengfei , Cecchetto, Sara Nicole, Kendrick, Michael L. , Pecorelli, Nicolò , Guarneri, Giovanni , Farooqui, Waqas , Tschuor, Christoph , Burgdorf, Stefan Kobbelgaard , Mühlhäusser, Julia , Gass, Jörn‐Markus , Koh, Ye-Xin, Seip, Tomas, Santibañes, Martín de , Todeschini, Letizia , Marchegiani, Giovanni, Belfil, Nadiya , Boggi, Ugo, Cappelle, Marie , Koerkamp, Bas Groot , Dutkowski, Philipp , Hackert, Thilo , Truty, Mark J. , Group, Outcomes for Total Pancreatectomy, Valle, Valentina , Giulianotti, Pier Cristoforo , Pessaux, Patrick, Thapa, Prabin , Kuzman, Matta , Pandanaboyana, Sanjay, He, Jin , Kendrick, Michael, Truty, Mark, Li, Zhihao , Groot Koerkamp, Bas , Müller, Philip C , Breuer, Eva , Vallorani, Alessia , Hansen, Carsten Palnæs , Guidetti, Cristiano , Campbell, Brady A. , Cecchetto, Sara Nicole, Gudmundsdottir, Hallbera , Starlinger, Patrick , Goh, Brian K P , Koh, Ye-Xin , Rebelo, Artur , Kleeff, Jorg H. , Marchegiani, Giovanni , Lesurtel, Mickaël , Machado, Marcel Autran C. , Kauffmann, Emanuele F. , Benedetto, Fabrizio Di , Roberts, Keith John , Nevler, Avinoam , Lavu, Harish , Nickel, Felix , He, Jing , Falconi, Massimo , Billeter, Adrian T. , Müller-Stich, Beat Peter , Group, Outcomes for Total Pancreatectomy, Halle-Smith, James Michael , Giannone, Fabio , Pessaux, Patrick , Sánchez‐Velázquez, Patricia , Maharjan, Dhiresh Kumar , Torres, Orlando Jorge Martins

Mayo Clinic

JAMA Surgery | November 12, 2025 | Volume: 161 | Issue: 1 | Pages: 50

10.1001/jamasurg.2025.4941 | PMID 41222926 Get It

Importance Total pancreatectomy (TP) is indicated for advanced pancreatic cancer or multifocal tumors. Furthermore, TP may be performed to avoid the risk of pancreatic fistula in selected patients to improve the perioperative risk profile. Objective To define reference values for TP based on a low-risk cohort treated at expert centers. Design, Setting, and Participants This multicenter study analyzed outcomes from patients undergoing primary TP for malignant or benign lesions from 25 international expert centers from January 2017 to November 2023. Low-risk patients undergoing TP (LR-TP) were without vascular resections or significant comorbidities. Exposures TP. Main Outcomes and Measures Twenty reference values were derived from the 75th or the 25th percentile of the median values of all centers. Outcomes of LR-TP were compared with a cohort of TP with vascular resection, TP due to high-risk pancreatic anastomosis, and the benchmark values for low-risk pancreatoduodenectomy. Results Of 994 patients, 333 (33.5%; median [IQR] age, 66 [58-72] years; 171 male [51.4%]) qualified as the LR-TP cohort. Reference values included blood loss (≤1000 mL), major complications (≤37%), 3-month postoperative mortality (<6%), and retrieved lymph nodes (≥29). Compared with TP with vascular resections, reference cutoffs were not met for major complications (51% vs LR-TP ≤37%) and 90-day mortality (11% vs LR-TP ≤6%). For TP due to high-risk anastomosis, failure to rescue rate (38% vs ≤6%) and 90-day mortality (11% vs LR-TP ≤6%) were not met. Compared with pancreatoduodenectomy, reference values for postoperative mortality were 3 times higher for LR-TP (≤2% vs ≤6%) and less for resected lymph nodes (≥16 vs ≥29). Conclusions and Relevance This case-control study provided global reference values for TP, indicating significantly higher postoperative morbidity and mortality compared with pancreatoduodenectomy. Perioperative morbidity of TP was especially increased in patients with vascular resections. These reference values can serve for quality control of pancreatic surgery.
The Definition of Cure in Colon Cancer
Pastorino, Alessandro , Liu, Heshan , Pederson, Levi , Martelli, Valentino , Gramont, Aimery de , Harkin, Andrea , Twelves, Chris , Souglakos, Ioannis , Goldberg, Richard M. , Puccini, Alberto , Sobrero, Alberto , Group, ACCENT/IDEA, Iveson, Timothy , Alberts, Steven R. , George, Thomas J. , Yothers, Greg , Labianca, Roberto , Taı̈eb, Julien , Schmoll, Hans‐Joachim , Wolmark, Norman , Saltz, Leonard B. , Goldberg, Richard M. , Kerr, Rachel , Lonardi, Sara , Yoshino, Takayuki , André, Thierry , Shi, Qian , Group, ACCENT/IDEA

Mayo Clinic

JAMA Oncology | October 2, 2025 | Volume: 11 | Issue: 12 | Pages: 1440

10.1001/jamaoncol.2025.3760 | PMID 41037274 Get It

Importance The definition of cure in stage II to III colon cancer (CC) remains unclear due to limitations in conventional end points, which include deaths and second primary tumors as events. These can complicate communication with patients regarding long-term outcomes. Objective To distinguish relapses from competing health-related events to classify long-term outcomes years after surgery and explore when the incidence of true relapses of the initial CC approaches 0% to define cure in this disease. Design, Setting, and Participants This pooled analysis of individual patient–level data from 15 phase 3 randomized clinical trials assessed time to CC-related relapse using Kaplan-Meier and Aalen-Johansen methods, with death and second primary tumors treated as competing risks. Cox regression models evaluated prognostic associations, stratified by sex, stage, and tumor. Patients with stage II to III CC who underwent adjuvant chemotherapy were included. All patients had undergone radical surgery for CC and received adjuvant chemotherapy with a median follow-up of at least 6 years. The Adjuvant Colon Cancer Endpoints (ACCENT) and the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) databases included adjuvant studies conducted between 1996 and 2015. Data were analyzed from February 2022 to June 2025. Exposures Adjuvant chemotherapy regimens varied across trials, including fluoropyrimidines alone or in combination with oxaliplatin or biologic agents. Main Outcomes and Measures The primary outcome was time to CC-related recurrence. The predefined threshold for cure was a recurrence risk below 0.5%. Results Of 35 213 included patients, 19 346 (54.9%) were male, and the mean (SD) age was 60.2 (10.8) years. The incidence rate of recurrence peaked at 6.4% (1993 of 31 373) between month 6 and month 12 and decreased continuously until year 10 of follow-up never exceeding 0.5%. Recurrence rate appeared to increase again after year 10 and peaked at 2.0% during year 12.5 to year 13, a pattern observed exclusively in the MOSAIC trial. Competing-event analysis revealed that death and second primary tumors inflated the apparent recurrence rate, especially for older patients. The overall cumulative incidence of relapse with death as competing risk was lower among female patients (hazard ratio, 0.58; 95% CI, 0.45-0.76; P < .001). Conclusions and Relevance In this pooled analysis of phase 3 randomized clinical trials, a recurrence rate less than 0.5% occurred after 6 years from surgery, supporting a practical definition of cure. Recognizing this milestone may improve patient communication, guide follow-up duration, and reduce unnecessary long-term surveillance.
Response to Biologics in Patients With Early-Onset Treatment-Naïve Metastatic Colorectal Cancer—An Aide et Recherche en Cancérologie Digestive Database Analysis
Jin, Zhaohui , Hubbard, Joleen M. , Eng, Cathy , Lieu, Christopher H. , Douillard, Jean‐Yves , Adams, Richard , Maughan, Tim , Cutsem, Eric Van , Venook, Alan P. , Lenz, Heinz‐Josef , Heinemann, Volker , Schmoll, H.J.E-V., Fuchs, Charles S. , Hecht, J. Randolph , Punt, Cornelis J. A. , Bokemeyer, Carsten , Gramont, Aimery de , Venook, Alan P , Maughan, Timothy S , Hubbard, Joleen , Adams, Richard , Van Cutsem, Eric , Lieu, Christopher , Jin, Zhaohui , Eng, Cathy , Dixon, Jesse G. , Stintzing, Sebastian , Saltz, Leonard B. , Falcone, Alfredo , Díaz‐Rubio, Eduardo , Punt, Cornelis J.A. , Tebbutt, Niall C. , Chibaudel, Benoist , Zalcberg, John , Yoshino, Takayuki , Shi, Qian

Mayo Clinic

JCO Oncology Advances | July 9, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available

10.1200/oa-24-00080 Get It

PURPOSE Colorectal cancer (CRC) incidence and mortality have decreased since the 1970s, but the incidence in young adults (<50 years, named early-onset CRC [eoCRC]) has been increasing. PATIENTS AND METHODS Individual patient data on 13,365 patients with metastatic CRC enrolled between 2000 and 2012 in 17 first-line randomized trials in the Aide et Recherche en Cancérologie Digestive database were pooled. The distribution of demographics, clinicopathologic features, biomarkers, and outcome data were summarized and compared by age groups. Progression-free survival (PFS) and overall survival (OS) were assessed by Kaplan-Meier curves and Cox models stratified by treatment arms within studies, adjusting for potential confounders. Predictive value of age group on clinical outcomes was evaluated by testing interaction effect between treatment and age variables. RESULTS Overall, 2,045 patients with eoCRC (median age, 42.5) and 11,320 patients with average-onset CRC (aoCRC; median age, 63.8) were included in this analysis. Within the eoCRC population, treatment with bevacizumab in addition to chemotherapy improved PFS (9.9 v 6.8 months; hazard ratio [HR], 0.66 [95% CI, 0.54 to 0.80]; P < .0001), which was similar to the findings in aoCRC population (9.4 v 7.3 months; HR, 0.73 [95% CI, 0.67 to 0.80]; P < .001; interaction P = .5415). However, epithelial growth factor receptor inhibitor (EGFRi) did not improve PFS in RAS wild-type (WT) patients with eoCRC who had left-sided primary tumors (8.3 v 8.9 months; HR, 1.20 [95% CI, 0.81 to 1.77]; P = .36), whereas EGFRi significantly improved PFS in the aoCRC population (9.9 v 8.5 months; HR, 0.74 [95% CI, 0.64 to 0.86]; P < .0001; interaction P = .083). CONCLUSION Treatment-naïve patients with metastatic eoCRC appear to derive similar benefit from bevacizumab as patients with aoCRC. However, patients with eoCRC with left-sided RAS/RAF WT tumors did not appear to derive benefit from first-line EGFRi.
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis
Chibaudel, Benoist , Raeisi, Morteza , Cohen, Romain , Yothers, Greg , Goldberg, Richard M. , Wolmark, Norman , Yoshino, Takayuki , Schmoll, Hans‐Joachim , George, Thomas J. , Shacham‐Shmueli, Einat , Gramont, Aimery de , Wolmark, Norman , Yoshino, Takayuki , Schmoll, Hans-Joachim , George, Thomas J , Shi, Qian , André, Thierry , De Gramont, Aimery , Yothers, Greg , Chibaudel, Benoist , Cohen, Romain , Bachet, Jean‐Baptiste , Kerr, Rachel , Lonardi, Sara , Shi, Qian , André, Thierry

Mayo Clinic

Journal of Clinical Oncology | September 4, 2024 | Volume: 42 | Issue: 35 | Pages: 4187-4195

10.1200/jco.24.00394 | PMID 39231393 Get It

PURPOSE The adjuvant treatment for stage III colon cancer (CC) is chemotherapy combining fluoropyrimidine (FP) and oxaliplatin (OX). FP regimen plus OX (FPOX) may benefit in high-risk stage II CC. We performed a pooled analysis of pivotal MOSAIC and C-07 studies evaluating FPOX for the treatment of high-risk stage II CC according to prognostic factors, number of high-risk factors, and current clinicopathologic risk classification on the basis of T stage, tumor perforation, and number of lymph nodes examined. PATIENTS AND METHODS One thousand five hundred and ninety-five patients with stage II CC receiving FP or FPOX were pooled. The overall survival (OS) benefit of OX was analyzed using Kaplan-Meier curves and unadjusted Cox models stratified by study. Three thousand and fifty-nine patients with stage III CC were used only for interaction tests between the allocated chemotherapy and stage. RESULTS In the pooled analysis of stage II patients, independent prognostic factors in multivariable analysis were sex, age, perforation/obstruction, and tumor sidedness. There was a significant interaction in OS between stage and allocated chemotherapy with hazard ratios (HRs) of 1.03 for stage II (95% CI, 0.82 to 1.29; P = .813) and 0.82 for stage III (95% CI, 0.73 to 0.92; P = .001; P int = .073). There was no benefit from the addition of OX to FP for any of the prognostic factors. The number of high-risk factors tested was not predictive of OX benefit. According to the currently agreed clinicopathologic risk classification, no OS benefit of OX was observed, as HR was 0.86 (95% CI, 0.63 to 1.18; P = .349). CONCLUSION No OS benefit of adjuvant OX was found in high-risk stage II CC, regardless of the definition used to characterize tumors as having a high risk for recurrence. Hence, our analysis suggests that OX should not be the standard of care for adjuvant chemotherapy for stage II CC, even in high-risk patients.
Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction
Barbier, Emilie, Burmeister, Bryan , Cunningham, David , Grilli, Maurizio , Hofheinz, Ralf‐Dieter , Kieser, Meinhard , Langley, Ruth E. , Lordick, Florian , Mauer, Murielle , Michalski, Christoph , Nankivell, Matthew , Stahl, Michael , Urba, Susan G., Lanschot, Jan van, Vordermark, Dirk , Walsh, T. N. , Proctor, Tanja, Vey, Johannes A. , Cunningham, David , Ronellenfitsch, Ulrich , Friedrichs, Juliane , Bass, Gary Alan , Eyck, Ben M. , Kleeff, Jorg H. , Klevebro, Fredrik , Lutz, Manfred Paul , Michl, Patrick , Nilsson, Magnus , Seide, Svenja , Shah, Manish A , Shi, Qian , Ychou, Marc

Mayo Clinic

JAMA Network Open | August 2, 2024 | Volume: 7 | Issue: 8 | Pages: e2425581

10.1001/jamanetworkopen.2024.25581 | PMID 39093560 Get It

ImportanceThe prognosis of patients with adenocarcinoma of the esophagus and esophagogastric junction (AEG) is poor. From current evidence, it remains unclear to what extent preoperative chemoradiotherapy (CRT) or preoperative and/or perioperative chemotherapy achieve better outcomes than surgery alone.ObjectiveTo assess the association of preoperative CRT and preoperative and/or perioperative chemotherapy in patients with AEG with overall survival and other outcomes.Data SourcesLiterature search in PubMed, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, ClinicalTrials.gov, and International Clinical Trials Registry Platform was performed from inception to April 21, 2023.Study SelectionTwo blinded reviewers screened for randomized clinical trials comparing preoperative CRT plus surgery with preoperative and/or perioperative chemotherapy plus surgery, 1 intervention with surgery alone, or all 3 treatments. Only data from participants with AEG were included from trials that encompassed mixed histology or gastric cancer. Among 2768 initially identified studies, 17 (0.6%) met the selection criteria.Data Extraction and SynthesisThe Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed for extracting data and assessing data quality by 2 independent extractors. A bayesian network meta-analysis was conducted using the 2-stage approach.Main Outcomes and MeasuresOverall and disease-free survival, postoperative morbidity, and mortality.ResultsThe analyses included 2549 patients (2206 [86.5%] male; mean [SD] age, 61.0 [9.4] years) from 17 trials (conducted from 1989-2016). Both preoperative CRT plus surgery (hazard ratio [HR], 0.75 [95% credible interval (CrI), 0.62-0.90]; 3-year difference, 105 deaths per 1000 patients) and preoperative and/or perioperative chemotherapy plus surgery (HR, 0.78 [95% CrI, 0.64-0.91]; 3-year difference, 90 deaths per 1000 patients) showed longer overall survival than surgery alone. Comparing the 2 modalities yielded similar overall survival (HR, 1.04 [95% CrI], 0.83-1.28]; 3-year difference, 15 deaths per 1000 patients fewer for CRT). Similarly, disease-free survival was longer for both modalities compared with surgery alone. Postoperative morbidity was more frequent after CRT plus surgery (odds ratio [OR], 2.94 [95% CrI, 1.01-8.59]) than surgery alone. Postoperative mortality was not significantly more frequent after CRT plus surgery than surgery alone (OR, 2.50 [95% CrI, 0.66-10.56]) or after chemotherapy plus surgery than CRT plus surgery (OR, 0.44 [95% CrI, 0.08-2.00]).Conclusions and RelevanceIn this meta-analysis of patients with AEG, both preoperative CRT and preoperative and/or perioperative chemotherapy were associated with longer survival without relevant differences between the 2 modalities. Thus, either of the 2 treatments may be recommended to patients.
Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study
Reinhardt, Maximilian, Ehst, Benjamin D. , Weiss, Jonathan , Sluzevich, Jason C. , Reygagne, Pascal , Wohlrab, Johannes , Fazel, Nasim , Muscianisi, Elisa , Fan, Heng , Hampele, Isabelle, Compagno, Nicolò , Sluzevich, Jason, Sluzevich, Jason C , Passeron, Thierry , Sticherling, Michael , Hertl, Michael

Mayo Clinic

British Journal of Dermatology | May 9, 2024 | Volume: 191 | Issue: 5 | Pages: 680-690

10.1093/bjd/ljae181 | PMID 38735684 Get It

Abstract Background Patients with lichen planus (LP) refractory to available therapies often experience a high disease burden, representing a population with a clear unmet need for new treatments. Objectives To evaluate the efficacy and safety of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven cutaneous LP (CLP), mucosal LP (MLP) or lichen planopilaris (LPP) that is inadequately controlled by topical corticosteroids. Methods PRELUDE was a randomized double-blind placebo-controlled phase II proof-of-concept study that enrolled patients with CLP, MLP or LPP. Eligible patients were randomized to either secukinumab 300 mg every 4 weeks for 32 weeks (SECQ4W) or placebo for 16 weeks followed by secukinumab 300 mg every 2 weeks (SECQ2W) for 16 weeks. The primary endpoint was achievement of the newly designed Investigator’s Global Assessment (IGA) score ≤ 2 at week 16. Results Overall, 111 patients were randomized (n = 37 each) to CLP, MLP and LPP cohorts. As the proof-of-concept criteria were not met for any of the three cohorts, the primary objective was not met. A numerically higher proportion of patients achieved IGA ≤ 2 response at week 16 with SECQ4W vs. placebo in the MLP {37.5% [95% credibility interval (Crl) 20.3–57.2] vs. 23.1% (95% Crl 6.5–49.2)} and LPP cohorts [37.5% (95% Crl 20.2–57.3) vs. 30.8% (95% Crl 10.8–57.6)]. In the LPP cohort, a sustained response for IGA ≤ 2 from week 16 to week 32 was achieved with SECQ4W (week 16, 37.5%; week 32, 45.8%), and a substantial improvement was observed in IGA ≤ 2 response in patients from this cohort who switched from placebo (week 16, 30.8%) to SECQ2W after week 16 (week 32, 63.6%). The safety profile was consistent with the known profile of secukinumab and showed no new or unexpected signals. Conclusions PRELUDE is the first randomized controlled basket trial evaluating interleukin (IL)-17A inhibition with secukinumab across three subtypes of LP. Secukinumab was well tolerated and safe, showing different response rates across the three subtypes, with numerical IGA improvements in MLP and LPP, and no response in CLP. The study raises the question of a differential role of IL-17A across LP subtypes. The novel IGA score showed significant correlation with both patient- and physician-reported outcome measurements.